NASDAQ: DMIIU
Drugs Made In America Acquisition II Corp Stock

$9.96-0.03 (-0.3%)
Updated Sep 26, 2025
DMIIU Price
$9.96
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$9.95
52 Week High
$9.99
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.53
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

DMIIU Overview

A SPAC (blank check company) incorporated in the Cayman Islands to pursue a business combination. The company aims to focus on pharmaceutical / drug sector targets to reduce U.S. reliance on global drug manufacturing. Each unit consists of one ordinary share and one right to receive one-tenth of a share upon completion of a qualifying business combination.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine DMIIU's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Shell Company

Industry Rating
F
DMIIU
Ranked
#12 of 29

Top Ranked Stocks in Industry

View Top Shell Company Stocks

Be the first to know about important DMIIU news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (6)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMIIU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DMIIU's short-term liabilities ($327.51k) exceed its short-term assets ($11.57k)
Short-term Liabilities Financials
DMIIU's short-term assets ($11.57k) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
DMIIU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more DMIIU due diligence checks available for Premium users.

Valuation

DMIIU's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%

Assets to liabilities

Assets
$113.4k
Liabilities
$327.5k
Debt to equity
-1.53
DMIIU's short-term liabilities ($327.51k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMIIU's short-term assets ($11.57k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMIIU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMIIU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

DMIIU vs Shell Company Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AACIC$328.54M+0.65%N/A-38.29x
AACT$587.05M+6.87%35.15x-24.39x
AAM$462.61M0.00%-21.04x-51.88x
AFJK$69.30M0.00%49.22x-24.24x
AACB$299.29M+0.30%N/A-24.51x

Drugs Made In America Acquisition II Stock FAQ

What is Drugs Made In America Acquisition II's quote symbol?

(NASDAQ: DMIIU) Drugs Made In America Acquisition II trades on the NASDAQ under the ticker symbol DMIIU. Drugs Made In America Acquisition II stock quotes can also be displayed as NASDAQ: DMIIU.

If you're new to stock investing, here's how to buy Drugs Made In America Acquisition II stock.

What is the 52 week high and low for Drugs Made In America Acquisition II (NASDAQ: DMIIU)?

(NASDAQ: DMIIU) Drugs Made In America Acquisition II's 52-week high was $9.99, and its 52-week low was $9.95. It is currently -0.3% from its 52-week high and 0.1% from its 52-week low.

How much is Drugs Made In America Acquisition II's stock price per share?

(NASDAQ: DMIIU) Drugs Made In America Acquisition II stock price per share is $9.96 today (as of Sep 26, 2025).
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.